BMS-986517 Clinical Trials (2026): 1 Studies for Solid Tumours
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 BMS-986517 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Solid Tumours) and 315 total planned enrollment. 1 BMS-986517 clinical trial is actively recruiting at 8 U.S. sites across 6 states. Most recent activity: NCT07160725 (Aug 2028).
Where to Participate: All BMS-986517 Trial Sites in the U.S. (8 sites across 6 states)
Every actively recruiting BMS-986517trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CA | USC/Norris Comprehensive Cancer Center | Los Angeles90033 | NCT07160725 | Map |
| CA | University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange92868-3201 | NCT07160725 | Map |
| PA | UPMC Hillman Cancer Center | Pittsburgh15232 | NCT07160725 | Map |
| SD | Sanford Cancer Center | Sioux Falls57104 | NCT07160725 | Map |
| TX | START - Dallas Fort Worth | Fort Worth76104 | NCT07160725 | Map |
| TX | START San Antonio | San Antonio78229 | NCT07160725 | Map |
| UT | START Mountain Region | West Valley City84119 | NCT07160725 | Map |
| WA | Fred Hutchinson Cancer Center | Seattle98109 | NCT07160725 | Map |
BMS-986517 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1/P2 | 1 | 1 |
Recruiting BMS-986517 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | P1/P2 | Solid Tumours | 315 | Oct 2025 |
All BMS-986517 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | P1/P2 | recruiting | 315 | Bristol-Myers Squibb | Oct 2025 |
BMS-986517 clinical trials: frequently asked questions
- How many BMS-986517 clinical trials are there?
- 1 BMS-986517 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are BMS-986517 clinical trials recruiting in 2026?
- Yes — 1 BMS-986517 trial is actively recruiting in 2026, with 8 U.S. sites across 6 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is BMS-986517 being studied for?
- BMS-986517 is being studied for Solid Tumours. The trials are grouped by indication on this page.
- Who sponsors BMS-986517 clinical trials?
- The lead sponsor across the most BMS-986517 trials is Bristol-Myers Squibb. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming BMS-986517as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: